Clinical Trial Update: International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia [Phase 3]

View source ↗

Summary

An international Phase 3 trial evaluating oral lixivaptan for hypervolemic hyponatremia in heart failure patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Hyponatremia

Drugs mentioned

• Lixivaptan (lixivaptan)

Snippet

Sponsor: CardioKine Inc. | Conditions: Hypervolemic Hyponatremia | Phase 3 | Status: WITHDRAWN